Compare UNCY & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNCY | FLC |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 172.4M |
| IPO Year | 2021 | 2003 |
| Metric | UNCY | FLC |
|---|---|---|
| Price | $5.34 | $16.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $25.67 | N/A |
| AVG Volume (30 Days) | ★ 709.9K | 18.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $15.89 |
| 52 Week High | $8.74 | $18.09 |
| Indicator | UNCY | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 25.15 |
| Support Level | $4.81 | $15.89 |
| Resistance Level | $5.86 | $17.00 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 32.89 | 0.00 |
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.